ClearNote Health to Present Early Detection Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting

ClearNote Health to Present Early Detection Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting

ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, today announced it will present new multi-cohort validation data for its Avantect® Pancreatic Cancer Test at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 29 – June 2.

ASCO attendees are invited to meet with ClearNote Health’s scientific and medical leadership team, including newly appointed Chief Medical Officer Jeffrey Venstrom, MD, and Chief Scientific Officer Samuel Levy, PhD, to discuss the company’s latest clinical data, strategic commercialization progress, and vision for advancing early cancer detection.

“Pancreatic cancer remains one of the most lethal malignancies because it is often diagnosed too late for curative intervention,” said Dr. Venstrom. “We are excited to share new validation data at ASCO demonstrating the strong performance of our Avantect Pancreatic Cancer Test among individuals with elevated risk. This test complements existing diagnostic and risk assessment strategies and provides clinically actionable insights when earlier detection can make the greatest difference.”